HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.

AbstractPURPOSE:
The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor.
EXPERIMENTAL DESIGN:
In vitro class 1 PI3K enzyme and human tumor cell growth inhibition assays and in vivo five tumor xenograft models were used to show efficacy.
RESULTS:
In vitro, PKI-587 potently inhibited class I PI3Ks (IC(50) vs. PI3K-α = 0.4 nmol/L), PI3K-α mutants, and mTOR. PKI-587 inhibited growth of 50 diverse human tumor cell lines at IC(50) values of less than 100 nmol/L. PKI-587 suppressed phosphorylation of PI3K/mTOR effectors (e.g., Akt), and induced apoptosis in human tumor cell lines with elevated PI3K/mTOR signaling. MDA-MB-361 [breast; HER2(+), PIK3CA mutant (E545K)] was particularly sensitive to this effect, with cleaved PARP, an apoptosis marker, induced by 30 nmol/L PKI-587 at 4 hours. In vivo, PKI-587 inhibited tumor growth in breast (MDA-MB-361, BT474), colon (HCT116), lung (H1975), and glioma (U87MG) xenograft models. In MDA-MB-361 tumors, PKI-587 (25 mg/kg, single dose i.v.) suppressed Akt phosphorylation [at threonine(T)308 and serine(S)473] for up to 36 hours, with cleaved PARP (cPARP) evident up to 18 hours. PKI-587 at 25 mg/kg (once weekly) shrank large (∼1,000 mm(3)) MDA-MB-361 tumors and suppressed tumor regrowth. Tumor regression correlated with suppression of phosphorylated Akt in the MDA-MB-361 model. PKI-587 also caused regression in other tumor models, and efficacy was enhanced when given in combination with PD0325901 (MEK 1/2 inhibitor), irinotecan (topoisomerase I inhibitor), or HKI-272 (neratinib, HER2 inhibitor).
CONCLUSION:
Significant antitumor efficacy and a favorable pharmacokinetic/safety profile justified phase 1 clinical evaluation of PKI-587.
AuthorsRobert Mallon, Larry R Feldberg, Judy Lucas, Inder Chaudhary, Christoph Dehnhardt, Efren Delos Santos, Zecheng Chen, Osvaldo dos Santos, Semiramis Ayral-Kaloustian, Aranapakam Venkatesan, Irwin Hollander
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 17 Issue 10 Pg. 3193-203 (May 15 2011) ISSN: 1557-3265 [Electronic] United States
PMID21325073 (Publication Type: Journal Article)
Copyright©2011 AACR.
Chemical References
  • Antineoplastic Agents
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors
  • Triazines
  • gedatolisib
  • TOR Serine-Threonine Kinases
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Female
  • HCT116 Cells
  • Humans
  • Mice
  • Mice, Nude
  • Morpholines (pharmacology, therapeutic use)
  • Neoplasms (drug therapy, metabolism)
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • TOR Serine-Threonine Kinases (antagonists & inhibitors)
  • Treatment Outcome
  • Triazines (pharmacology, therapeutic use)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: